Companies /Healthcare

Arcturus Therapeutics Holdings Inc

NASDAQ: ARCT Biotechnology
$13.30
▼ $1.08 (−7.51%) today
Markets closed · 4:24am ET

Fundamentals

Market Cap
$396.9M
Revenue (TTM)
$29.4M
EPS (TTM)
$-3.33
52-Week Range
$6 – $24
Street Target
$22.30

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a biotechnology firm based in San Diego, California, specializing in the development of innovative mRNA medicines and vaccines. With a focus on addressing infectious diseases, liver, and respiratory rare conditions, Arcturus leverages its proprietary LUNAR lipid-mediated delivery and STARR mRNA technology platforms. The company's pipeline includes ARCT-810, a treatment for ornithine transcarbamylase deficiency in Phase 2 trials, ARCT-154, a COVID-19 vaccine candidate in Phase 3 trials in Vietnam, and ARCT-032, a potential therapy for cystic fibrosis.

ARCT Coverage